慢性淋巴细胞白血病:复发的治疗。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI:10.1038/leusup.2012.18

M Montillo

{"title":"慢性淋巴细胞白血病:复发的治疗。","authors":"M Montillo","doi":"10.1038/leusup.2012.18","DOIUrl":null,"url":null,"abstract":"Despite significant advances in the frontline treatment of chronic lymphocytic leukemia (CLL), patients eventually experience disease progression. Treatment selection of relapsed disease depends upon a variety of factors, including patient age, performance status, duration of response to initial therapy, type of prior therapy, disease-related manifestations and genetic abnormalities within the CLL cells. This presentation offers synthetic overview of the options in this field. ","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"1 Suppl 2","pages":"S31-2"},"PeriodicalIF":0.0000,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2012.18","citationCount":"1","resultStr":"{\"title\":\"Chronic lymphocytic leukemia: treatment of relapse.\",\"authors\":\"M Montillo\",\"doi\":\"10.1038/leusup.2012.18\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite significant advances in the frontline treatment of chronic lymphocytic leukemia (CLL), patients eventually experience disease progression. Treatment selection of relapsed disease depends upon a variety of factors, including patient age, performance status, duration of response to initial therapy, type of prior therapy, disease-related manifestations and genetic abnormalities within the CLL cells. This presentation offers synthetic overview of the options in this field. \",\"PeriodicalId\":91571,\"journal\":{\"name\":\"Leukemia supplements\",\"volume\":\"1 Suppl 2\",\"pages\":\"S31-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1038/leusup.2012.18\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/leusup.2012.18\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2012/8/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/leusup.2012.18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/8/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

尽管慢性淋巴细胞白血病(CLL)的一线治疗取得了重大进展，但患者最终会经历疾病进展。复发疾病的治疗选择取决于多种因素，包括患者年龄、身体状况、对初始治疗的反应持续时间、先前治疗的类型、疾病相关表现和CLL细胞内的遗传异常。本演示提供了该领域选项的综合概述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Chronic lymphocytic leukemia: treatment of relapse.

Despite significant advances in the frontline treatment of chronic lymphocytic leukemia (CLL), patients eventually experience disease progression. Treatment selection of relapsed disease depends upon a variety of factors, including patient age, performance status, duration of response to initial therapy, type of prior therapy, disease-related manifestations and genetic abnormalities within the CLL cells. This presentation offers synthetic overview of the options in this field.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Leukemia supplements

自引率

0.00%

发文量